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Previous studies have shown that human fetal adre-
nal gland from 17- to 20-week-old fetuses expressed
pituitary adenylate cyclase-activating polypeptide
(PACAP) receptors, which were localized on chromaf-
fin cells. The aim of the present study was to identify
PACAP receptor isoforms and to determine whether
PACAP can affect intracellular calcium concentration
([Ca2]i) and catecholamine secretion. Using primary
cultures and specific stimulation of chromaffin cells,
we demonstrate that PACAP-38 induced an increase in
[Ca2]i that was blocked by PACAP (6–38), was inde-
pendent of external Ca2, and originated from thapsi-
gargin-insensitive internal stores. The PACAP-trig-
gered Ca2 increase was not affected by inhibition of
PLC (preincubation with U-73122) or by pretreatment
of cells with Xestospongin C, indicating that the inosi-
tol 1,4,5-triphosphate-sensitive stores were not mobi-
lized. However, forskolin (FSK), which raises cytosolic
cAMP, induced an increase in Ca2 similar to that re-
corded with PACAP-38. Blockage of PKA by H-89 or
(Rp)-cAMPS suppressed both PACAP-38 and FSK cal-
cium responses. The effect of PACAP-38 was also abol-
ished by emptying the caffeine/ryanodine-sensitive
Ca2 stores. Furthermore, treatment of cells with or-
thovanadate (100 M) impaired Ca2 reloading of
PACAP-sensitive stores indicating that PACAP-38 can
mobilize Ca2 from secretory vesicles. Moreover,
PACAP induced catecholamine secretion by chromaf-
fin cells. It is concluded that PACAP-38, through the
PAC1 receptor, acts as a neurotransmitter in human
fetal chromaffin cells inducing catecholamine secre-
tion, through nonclassical, recently described, ryano-
dine/caffeine-sensitive pools, involving a cAMP- and
PKA-dependent phosphorylation mechanism.
Pituitary adenylate cyclase-activating polypeptide is a 38-
residue -amidated neuropeptide (PACAP-38)1 originally iso-
lated from the ovine hypothalamus for its ability to stimulate
cAMP formation in rat anterior pituitary cells. Processing of
PACAP-38 can generate a 27-amino acid amidated peptide
(PACAP-27) that exhibits 68% sequence identity with vasoac-
tive intestinal polypeptide (VIP), thus identifying PACAP as a
member of the VIP/secretin/glucagon superfamily of regulatory
peptides (1, 2).
The effects of PACAP are mediated through interaction with
two types of high affinity receptors: type I receptors are selec-
tively activated by PACAP, whereas type II receptors bind
PACAP and VIP with similar affinity (3). Three isoforms of
PACAP receptors have now been cloned and designated as
PACAP-specific receptor I (PAC1-R) (4, 5) and VIP/PACAP
mutual receptors 1 and 2 (VPAC1-R and VPAC2-R) (6, 7). Both
PAC1-R (type 1 receptors) and VPAC1-R/VPAC2-R (type 2 re-
ceptors) belong to the seven-transmembrane domain, G-pro-
tein-coupled receptor family, and are all positively coupled to
adenylyl cyclase (2). Eight isoforms of PAC1-R, resulting from
alternative splicing, have been characterized to date. These
variants display differential signal transduction properties
with regard to adenylyl cyclase and phospholipase C (PLC)
stimulation (1, 2). In addition to these classical signaling path-
ways, PACAP has been found to stimulate a Ca2-calmodulin
nitric oxide synthase (8) and mitogen-activated protein kinase
activity (9). These various transduction mechanisms are in-
volved in the neurotrophic activities exerted by PACAP (i.e.
inhibition of apoptosis and stimulation of neurite outgrowth)
during development (9–11).
PACAP and its receptors are actively expressed in the adre-
nal medulla (12–14). In particular, we have previously demon-
strated the occurrence of PACAP-38 (15) and PACAP binding
sites (16) in chromaffin cells from 16- to 20-week-old fetal
human adrenal glands. Activation of these receptors by
PACAP-38 causes stimulation of cAMP production and induces
a modest increase in inositol 1,4,5-triphosphate (IP3) formation
(16), suggesting a role for the neuropeptide in the developing
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adrenal gland. During the process of adrenal gland develop-
ment, pheochromoblasts originating from the neural crest mi-
grate throughout the fetal cortex, acquiring progressive differ-
entiation through contact with the steroidogenic cells (17, 18)
(for review see Ref. 19). However, the neuroendocrine regula-
tion of catecholamine release by chromaffin cells in the human
fetus has not been investigated.
Although PACAP is known to be a potent activator of cate-
cholamine secretion from rat and porcine adrenochromaffin
cells (20, 21), the differential coupling of PACAP receptor vari-
ants to the various Ca2 sources and to the adenylyl cyclase
and PLC signaling pathways is still poorly understood. In
particular, the effect of PACAP on fetal chromaffin cells has
never been investigated. The aim of the present study was
therefore to identify the PACAP receptor isoforms expressed in
the human fetal adrenal gland and to analyze the signaling
pathways responsible for PACAP-evoked [Ca2]i increase and
catecholamine secretion.
MATERIALS AND METHODS
Chemicals—The chemicals used in the present study were obtained
from the following sources: RNAqueousTM-4PCR purchased from Am-
bion (Austin, TX); dithiothreitol, p(dT)12–18, rRNasin Ribonuclease In-
hibitor, Moloney murine leukemia virus reverse transcriptase (RT) and
DNA ladder from Promega (Madison, WI); deoxy-NTPs and Taq DNA
polymerase from Amersham Pharmacia Biotech (Piscataway, NJ); Xes-
tospongin C, U73122, forskolin, thapsigargin, and H-89 from Calbio-
chem-Novabiochem Corp. (San Diego, CA); methacholine, sodium or-
thovanadate, nicotine, and DNase from Sigma-Aldrich Canada Ltd
(Oakville, Ontario, Canada); collagenase, MEM Eagle’s medium and
OPTI-MEM from Invitrogen (Burlington, Ontario, Canada); (Rp)-
cAMPS from Biomol (Plymouth Meeting, PA); Fluo-4 from Molecular
Probes (Eugene, OR); PACAP-38 was synthesized by the solid phase
methodology as previously described (22); and PACAP (6–38) was from
American Peptide Co. (Sunnyvale, CA). All other chemicals were of A
grade purity.
Retrieval and Preparation of Glands—Fetal adrenal glands were
obtained from fetuses aged 14–20 weeks (post fertilization) at the time
of therapeutic abortion. Fetal ages were estimated by foot length and
time after menstruation, according to Steeter et al. (23). The project was
approved by the human subject review committee of our institution.
After retrieval, glands were cleansed of fat and processed immediately
for cellular or RNA preparation.
RT-PCR—RNA isolation and complementary DNA (cDNA) synthe-
sis: total RNA was isolated from whole human fetal adrenal glands (14,
17, and 20 weeks of gestation), and fetal human brain (18 weeks) using
RNAqueousTM-4PCR, according to the manufacturer’s recommenda-
tions. RNA content and quality were determined photometrically. 5 g
of total RNA was denatured (70 °C, 10 min) and reverse-transcribed in
the presence of 200 M p(dT)12–18 at 42 °C for 50 min in 20 l of 1 RT
buffer (25 mM Tris-HCl, pH 8.3, 37.5 mM KCl, 1.5 mM MgCl2) contain-
ing: 15 mM dithiothreitol, 200 M deoxy-NTPs, 25 units of rRNasin
ribonuclease inhibitor, and 200 units of Moloney murine leukemia virus
RT. Inactivation of the enzyme (70 °C, 10 min) was followed by glycer-
aldehyde-3-phosphate dehydrogenase PCR to assess the quality of the
cDNA template (24).
PCR Amplifications—cDNA samples (2 l) were used for subsequent
PCR amplifications in 50 l of 1 PCR buffer (10 mM Tris, pH 8.3, 50
mM KCl, 1.5 mM MgCl2) containing 200 M deoxy-NTPs, 10 pmol of each
of the sense and antisense primers, and 2.5 units of Taq DNA polym-
erase. Primers used for the amplification of PAC1-R splice variant
cDNAs were sense, 5-CTTGTGCAGAAACTTCAGTCTCCAGACATG,
and antisense, 5-TCGGTGCTTGAAGTCCACAGCGAAGTAACGGTT-
CACCTT (25), corresponding to base sequences 1235–1264 and
1499–1537 of human PAC-R (4). These primers flank the insertion site
of 84-bp cassettes (5) and were designed to give a 303-bp amplicon for
the normal (null) PACAP receptor, a 387-bp amplicon for the SV-1 or
SV-2 splice variants (insertion of one 84-bp cassette), and a 471-bp
amplicon for the insertion of two cassettes. PCR was carried out in a
PerkinElmer Life Sciences (geneAmp PCR System 2400) thermocycler
at 94 °C for 2 min followed by 35 cycles at 94 °C for 30 s, 61 °C for 30 s,
72 °C for 1 min, and a final extension at 72 °C for 5 min. Primers used
for the amplification of VPAC1-R cDNA were the sense, 5-ATGTGCA-
GATGATCGAGGTG, and antisense, 5-TGTAGCCGGTCTTCACAGAA
(26), corresponding, respectively, to base sequences 127–146 and
431–450 of human VPAC1-R (6). PCR was carried out at 94 °C for 2 min
followed by 30 cycles at 94 °C for 30 s, 55 °C for 30 s, 72 °C for 1 min,
and a final extension at 72 °C for 5 min, giving a 324-bp amplicon.
Primers used for the amplification of VPAC2-R cDNA were the sense,
5-TCAAACAGAAAAACACAAAGC, and antisense, 5-ACCTGTTCCT-
GTCCTTCATCC (7), corresponding, respectively, to base sequences
294–314 and 653–673 of human VPAC2-R (7). PCR was carried out at
95 °C for 2 min, followed by 35 cycles at 95 °C for 1 min, 58 °C for 1 min,
72 °C for 1 min, and a final extension at 72 °C for 5 min, giving a 380-bp
amplicon.
In every PCR experiment, amplification in the absence of cDNA and
in the presence of 2 g of RNA was performed as a control (not shown).
Negative controls using cDNA templates from NCI-H295R and Chinese
hamster ovary cells were performed (not shown). PCR products (10 l)
were analyzed on 2% (w/v) agarose gel and visualized by ethidium
bromide staining. Length of PCR products was estimated using a
100-bp DNA ladder. Identification of the PCR products was confirmed
by enzymatic digestion and electrophoresis on 3% (w/v) agarose with a
25-bp DNA ladder (not shown). Experiments were performed with RNA
isolated from three different adrenal glands from 14-, 17-, and 20-week-
old human fetuses. Three experiments were performed for each age.
Cell Culture—Glands were processed as described previously (16).
Whole tissues from one or two glands were used for each cell prepara-
tion, without separation of fetal zone, neocortex, or chromaffin cells.
Briefly, small portions of glands (1–2 mm3) were dissociated with col-
lagenase (2 mg/ml) and DNase (25 g/ml) in Eagle’s minimal essential
medium containing 2% antibiotics. After three 20-min incubations, cells
were dissociated, filtered, and centrifuged for 10 min at 100  g. The
cell pellet was suspended in OPTI-MEM medium containing 2% fetal
calf serum, antibiotics, and antimycotics. Cells were plated at a density
of 2  105 on plastic coverslips (25 mm). Cells were grown for 3 days
in a humidified atmosphere of 95% air/5% CO2, at 37 °C.
Calcium Measurement—For dye loading, cells were incubated for 30
min at 37 °C in the physiological medium OPTI-MEM containing 4 M
of the fluorescent calcium indicator Fluo-4/AM. Hydrolysis was per-
formed for 30 min at 37 °C in a medium containing: 140 mM NaCl; 5.4
mM KCl; 2 mM CaCl2; 1 mM MgCl2; 10 mM HEPES, pH 7.4; and 1 g/liter
glucose. The coverslips were then mounted on the stage of an inverted
microscope (Nikon Diaphot, Mississauga, Ontario, Canada). The light
source was generated by a 100-watt mercury lamp. Band-pass filters
(450–490 nm) and (520–560 nm) were used for excitation and emission,
respectively. The emitted light was recorded by a photon-counting unit.
Calcium calibration was performed as described previously (27). How-
ever, because calcium dye properties may be different in cytoplasmic
and nucleoplasmic compartments (28), [Ca2]i should be considered
only as semiquantitative data (29).
Catecholamine Secretion—An amperometric technique was used to
record secretion from chromaffin cells as described previously (30).
Briefly, a 5-m carbon fiber electrode (Ala Scientific Instrument Inc.,
Westbury, NY) connected to a Patch Clamp PC-501A amplifier (Warner
Instrument Corp., Hamden, CT) modified for voltametry was positioned
in close proximity of a cell. The potential of the electrode was fixed to
800 mV, and current traces were filtered at 4 kHz and recorded on a
DAS-75 digital recorder (Dagan Corp., Minneapolis, MN).
Data Analysis—Curves were fitted with SigmaPlot (version 7.0,
Chicago, IL). The data are presented as means  S.E. from the number
of experiments indicated in the legends or in the text. Statistical anal-
yses of the data were performed using the one-way analysis of variance
test. Homogeneity of variance was assessed by Bartlett’s test, and p
values were obtained from Dunnett’s tables.
RESULTS
Molecular Identification of PACAP Receptors—Using autora-
diography, we have previously shown that PACAP receptors in
the human fetal adrenal gland were localized only on chromaf-
fin cells (16). An RT-PCR approach was used to identify the
PACAP receptor subtypes expressed in adrenal glands from 14-
to 20-week-old fetuses. As indicated under “Materials and
Methods,” PAC1-R splice variants were discriminated using
primers flanking the insertion site of the 84-bp cassettes. As
shown in Fig. 1A, two bands were detected: a 303-bp band
corresponding to the short form of the receptor and a 387-bp
band corresponding to an isoform containing a single insertion
cassette. Amplicons of 324 and 380 bp corresponding, respec-
tively, to VPAC1-R and VPAC2-R sequences were also detected
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in all fetal adrenal glands. However, based on our previous
results, these receptors have a more diffuse distribution
throughout the adrenal gland, whereas PAC1-Rs are only de-
tected in chromaffin cells (16). Expression of the PAC1-R,
VPAC1-R, and VPAC2-R RNAs was also observed in 18-week-
old fetal brains. Amplification of glyceraldehyde-3-phosphate
dehydrogenase (Fig. 1D) confirmed that cDNA was present in
each reaction.
Effect of PACAP on Cytosolic Ca2 Concentration—Chromaf-
fin cells, which gather into small clusters with numerous pro-
cesses, could be easily distinguished from the large individual
fetal steroidogenic cells (Fig. 2, white arrows). Measurements
of [Ca2]i were performed on peripheral cells of the clusters,
selected by a pinhole placed in the optical path (Fig. 2, aster-
isk). Mean [Ca2]i in chromaffin cells incubated in medium
containing 2 mM Ca2 was 77 nM  7 (n  6) in resting
conditions. Application of 1  109 M PACAP-38 induced a
transient elevation of [Ca2]i (Fig. 3A). This [Ca
2]i increase
was characterized by a rapid upstroke followed by a slower
decrease to basal levels. The time course of the decrease could
be fitted by a monoexponential function. At a concentration of
1  109 M PACAP-38, the time constant  was 57.3  7.4 s
(n  9). In Ca2-free medium (0 Ca2 plus 1 mM EGTA),
application of 1  109 M PACAP-38 provoked an increase in
[Ca2]i similar to that recorded in 2 mM Ca
2-containing me-
dium (Fig. 3B) with a time constant (49.7  3.5 s; n  11) that
was not significantly different (p  0.34), suggesting that
PACAP-38 causes mobilization of intracellular Ca2 stores.
Indeed, application of Ni2, a known Ca2 channel blocker,
during the decreasing phase of the Ca2 response, had no effect
on the kinetics of the Ca2 spike induced by application of
PACAP-38 (1  109 M) in 2 mM Ca2-containing medium,
whereas a second application of PACAP-38 in the presence of
Ni2 provoked a Ca2 response similar to that obtained in the
absence of the blocker (Fig. 3C). Application of increasing con-
centrations of PACAP-38 resulted in a dose-dependent rise in
the amplitude of the [Ca2]i response with an ED50 value of 5
nM (Fig. 3D), a value similar to that obtained (2.6 nM) by
measuring the [Ca2]i increase on hippocampal neurons (31).
Administration of repeated pulses of PACAP-38 (1 109 M) at
various time intervals induced a reproducible [Ca2]i increase,
FIG. 1. Expression of PACAP receptor isoforms in the human
fetal adrenal gland. cDNA from adrenal glands 14-, 17-, and 20-week-
old fetuses and from 18-week-old human fetal brain (HFB) were ampli-
fied using oligonucleotide primers encoding: A, nucleotide sequences
1235–1264 and 1499–1537 of the PAC1 receptor, designed to give three
possible amplicons of 303, 387, and 471 bp; B, nucleotide sequences
127–146 and 431–450 of the human VPAC1 receptor; and C, nucleotide
sequences 294–314 and 653–673 of the human VPAC2 receptor. D,
amplification of glyceraldehyde-3-phosphate dehydrogenase (192 bp)
was used to ensure RNA quality and amounts.
FIG. 2. Phase-contrast morphology of a human fetal adrenal
gland cell culture. A and B, representative illustrations from two
different cell cultures. After 24 h in culture, chromaffin cells (CC) were
gathered in small clusters that exhibited several long processes. Cells
from the fetal zone (white arrows) were easily identified by their size
and their polygonal morphology. Black arrows indicate contact between
a chromaffin cell extension and a fetal cell. The asterisk indicates a cell
selected by a pinhole placed in the optical path. Scale bars represent
10 m.
FIG. 3. Effects of PACAP-38 on [Ca2]i in human fetal chromaf-
fin cells. A, PACAP-38 (P) 1  109 M was applied in a medium
containing 2 mM of Ca2 (representative of 9 cells from 9 different cell
cultures). Scale: vertical, 25 nM; horizontal, 50 s. B, PACAP-38 (P) 1 
109 M was applied in a Ca2-free medium containing 1 mM EGTA
(representative of 11 cells from 9 different cell cultures). Scale: vertical,
20 nM; horizontal, 50 s. C, application of Ni2 (500 M) during the falling
phase of the Ca2 response induced by PACAP-38 (P) 1 109 M had no
effect on the time course of the response nor on the subsequent response
induced by a new application of PACAP-38 (representative of 5 cells
from 5 different cell cultures). Scale: vertical, 11 nM; horizontal, 100 s.
D, relationship between the concentration of PACAP-38 and the Ca2
increase (n  3, 5, 15, 3, 3, and 3 for 0.01, 0.1, 1, 40, 200, and 1000 nM
of PACAP-38, respectively). The experimental points were fitted by the
logistic function with an ED50 of 5 nM.
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even when applied at very short intervals (Fig. 4A). The am-
plitudes of the responses to any of the four pulses applied were
not significantly different (Fig. 4B). To further confirm that the
PACAP-induced [Ca2]i increase was due to the activation of
the PAC1-R type receptor, we used PACAP (6–38), a PAC1
receptor-specific antagonist shown to inhibit the activation of
adenylyl cyclase with a Ki of 7 nM (32). A first application of
PACAP-38 (1  107 M) triggered a Ca2 response as previ-
ously described. The antagonist PACAP (6–38) was then ap-
plied (10 M) for a 10-min period and followed by a second
application of PACAP-38, at the same concentration, which
induced a lower Ca2 increase (Fig. 4C). For concentrations of
PACAP (6–38) of 0.3, 1, and 10 M, the Ca2 response to
PACAP-38 (1  107 M) was reduced to 48.5  12% (n  4),
25  2% (n  2), and 6.9  3.4% (n  4) of the control,
respectively (Fig. 4D).
Nature of the Intracellular Ca2 Pool—We have previously
shown that PACAP-38 induces a 3.4-fold increase in cAMP
production and a modest increase in IP3 formation in fetal
human chromaffin cells (16). In the present study, we first
investigated whether or not the PACAP-sensitive Ca2 pool
was responsive to thapsigargin (TG), a known inhibitor of the
sarco(endo)plasmic reticulum Ca2-ATPase pumps but without
effect on plasma membrane Ca2-ATPase activity (33). In one
series of experiments, the cells were bathed in Ca2-free me-
dium. Application of PACAP-38 (1  109 M) produced an
increase in Ca2 as described previously (Fig. 5A). The subse-
quent application of TG (4 M) triggered an additional increase
in [Ca2]i resulting from blockage of the sarco(endo)plasmic
reticulum Ca2-ATPase pumps. When PACAP-38 was applied
further, the amplitude and kinetics of the Ca2 increase were
similar to those obtained prior to TG application, indicating
that TG and PACAP-38 did not mobilize the same Ca2 pool(s).
In a second series of experiments, cells were preincubated for
30 min in a calcium-free medium containing 8 M TG. Under
these conditions, the Ca2 response to TG (4 M) was greatly
reduced, whereas the response to PACAP-38 (2.5 109 M) was
not affected (Fig. 5B).
In some other cell types, it has been shown that PACAP
receptors are coupled to PLC through a Gq/11 protein to produce
diacylglycerol and IP3 (34). In the specific case of human fetal
chromaffin cells, we previously found that IP3 production is
relatively low (16). Hence, experiments were performed to as-
sess the putative role of IP3-sensitive calcium pools in the
PACAP-induced increase in [Ca2]i. Cells were treated with
U-73122 compound, a specific PLC inhibitor (35), at a concen-
tration of 1 M for 18 h. PACAP-38 (1 109 M) was then added
in the presence or absence of Ca2 in the external medium as
described above. In five different cells, the amplitude as well as
the kinetics of the Ca2 response to PACAP-38 were similar to
those obtained in control cells (Fig. 6A), indicating that the
Ca2 increase was not dependent on IP3-sensitive pools. Fur-
ther confirmation of these results was provided from experi-
ments using Xestospongin C (XeC), a potent specific blocker of
the inositol 1,4,5-triphosphate (IP3) receptors (36). In this ex-
perimental design, PACAP-38 (1  109 M) was first applied to
induce a [Ca2]i increase. XeC (20 M) was then applied for 10
min prior to a second application of PACAP-38. Fig. 6B shows
that the amplitude of the Ca2 increase was not affected by
XeC, thus indicating that IP3-sensitive Ca
2 pools are not
FIG. 4. Frequency dependence of the PACAP-induced Ca2 in-
crease in the human fetal adrenal gland. A, four identical concen-
trations of PACAP-38 (P) 1 109 M were applied on the same cell. Note
that the four Ca2 increases are identical with no apparent desensiti-
zation. Scale: vertical, 20 nM; horizontal, 100 s. B, compilation of data
obtained in three different cells from three different glands where
PACAP-38 was applied four successive times indicated by 1, 2, 3, and 4
corresponding to the first, second, third, and fourth PACAP-38 appli-
cations. Data are normalized to the first response. C, effect of PACAP
(6–38) on the PACAP-induced Ca2 increase in the human fetal adrenal
gland. A first application of PACAP-38 (P) (1  107 M), which elicited
a Ca2 increase, was followed by application of 10 M of the PAC1-R
antagonist PACAP (6–38) (I). After 10 min, PACAP-38 (P) (1  107 M)
was further applied. Scale: vertical, 13 nM; horizontal, 20 s. D, inhibi-
tion of the PACAP-38 (1  107 M) Ca2 responses by PACAP (6–38)
applied during 10 min; 1, normalized Ca2 increase in control condition;
2, blockage of the Ca2 response by 0.3 M PACAP (6–38) obtained in
four different cells from three different glands; 3, blockage of the Ca2
response by 1 M of PACAP (6–38) obtained in two different cells from
two different glands; 4, blockage of the Ca2 response by 10 M PACAP
(6–38) obtained in four different cells from three different glands. *,
significantly different at the p  0.05 level.
FIG. 5. Lack of sensitivity of the PACAP-induced Ca2 increase
to thapsigargin in the human fetal adrenal gland. A, a first ap-
plication of PACAP-38 (P) 1  109 M, which elicited a Ca2 increase,
was followed by application of 4  106 M of thapsigargin (TG) to
deplete the TG-sensitive Ca2 pools. A subsequent application of
PACAP-38 at the same concentration triggered a Ca2 response, which
was not affected by TG (representative of three cells, three different
cells cultures); experiments conducted in a Ca2-free medium. Scale:
vertical, 14 nM; horizontal, 100 s. B, the cells were preincubated in a
medium containing 8  106 M of TG during 30 min. Application of
PACAP-38 (P) 2.5  109 M elicited a Ca2 increase similar to the
response obtained in control conditions, whereas TG (4  106 M)
elicited a slight increase indicating that the TG-sensitive Ca2 stores
are depleted (representative of four cells, three different cells cultures).
Scale: vertical, 38 nM; horizontal, 100 s.
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involved. Similar results were obtained from five different
cells.
Involvement of a cAMP-sensitive calcium pool in the PACAP
response was tested by directly activating cAMP production
with forskolin (FSK). Fig. 7A demonstrates that FSK (1  105
M) and PACAP-38 (1  109 M) triggered identical calcium
increases. Similar results were obtained in the absence of Ca2
in the bathing medium (data not shown, n  3). The involve-
ment of a PKA-dependent phosphorylation step in the increase
in Ca2 triggered by PACAP was assessed by using H-89, an
inhibitor of PKA. When cells were pretreated with H-89 (10 M)
for 15 min, subsequent stimulation with PACAP-38 failed to
trigger a Ca2 increase (Fig. 7B, n  7). The FSK-triggered
Ca2 increase was also abolished (Fig. 7B, n  4). When (Rp)-
cAMPS (1 mM), a more specific membrane-permeant inhibitor
of PKA was used, the response to PACAP-38 (2  107 M), but
not to TG, was abolished (Fig. 7C, n  4).
Caffeine is known to activate ryanodine channels and to induce
[Ca2]i increase in numerous cell types (37). Application of caf-
feine (20 mM) to chromaffin cells induced an increase in [Ca2]i
(Fig. 8A). More importantly, the Ca2 response to PACAP-38
(1 109 M) was significantly decreased following caffeine appli-
cation to chromaffin cells (51  6.7%, n  5). Similar results
were obtained with ryanodine (20 M, n  4, data not shown).
A recent study reported that neuroendocrine cells contained
dense core secretory vesicles that could constitute a dynamic
Ca2 store, whereby the P-type Ca2 pump was responsible for
Ca2 uptake in these secretory vesicles (38). To assess such
putative participation, we used orthovanadate at 100 M, a
concentration known to inhibit the ATP-dependent P-type
Ca2 pump. In Ca2-free medium, cells were first challenged
with PACAP-38 (1 109 M) followed by application of Na3VO4
(100 M) for 10 min. Thereafter, the first addition of PACAP-38
induced a Ca2 response not significantly different in ampli-
tude (9.2  9% decrease, n  6) from that obtained prior to
adding Na3VO4. However, subsequent applications of
PACAP-38 gave rise to a lower amplitude of Ca2 increase
(63% and 86% for the second and third PACAP-38 applica-
tions, respectively) (Fig. 8B). Data obtained from three differ-
ent cell cultures are summarized in Fig. 8C.
Functional Properties of Chromaffin Cells—Activation of
cholinergic receptors in chromaffin cells is the main stimulus
for mobilizing Ca2 to induce catecholamine secretion (39).
Hence, experiments were undertaken to determine if chromaf-
fin cells from 17- to 20-week-old human fetuses express func-
tional cholinergic receptors. Release of Ca2 from IP3-sensitive
Ca2 pools was tested using methacholine, a muscarinic recep-
tor agonist. Fig. 9A shows that application of methacholine (10
M) to chromaffin cells induced a large, transient increase of
[Ca2]i followed by a plateau indicating an influx of Ca
2as
previously shown for guinea pig adrenal chromaffin cells (40).
Moreover, voltage-dependent Ca2 channels are functional in
17- to 20-week-old human fetal adrenal chromaffin cells. In-
deed, membrane depolarization caused by activation of nico-
tinic receptors with nicotine (10 M) induced a [Ca2]i increase
FIG. 6. PACAP-38 does not mobilize IP3-sensitive Ca
2 stores
in the human fetal adrenal glands. A, cells were preincubated for
18 h in the presence of the PLC inhibitor U73122 (1  106 M). Exper-
iments were conducted in a Ca2-free medium. This treatment did not
modify the PACAP-38 (P) 1 109 M-induced Ca2 increase (represent-
ative of five cells, three different cell cultures). Scale: vertical, 20 nM;
horizontal, 50 s. B, Xestospongin C (XeC) 20  106 M was applied after
a first response elicited by PACAP-38 (P) 1  109 M. The second
application of PACAP-38 (P) triggered a similar Ca2 increase (repre-
sentative of five cells, five different cells cultures). Scale: vertical, 14 nM;
horizontal, 100 s.
FIG. 7. PACAP-38 uses the cAMP/PKA pathway to trigger Ca2
increase in the human fetal adrenal gland. A, forskolin (FSK) 1 
105 M triggered a Ca2 increase similar to that evoked by PACAP-38
(P) 1  109 M (representative of three cells, three different cell cul-
tures). Scale: vertical, 38 nM; horizontal, 100 s. B, cells were treated
with H-89 (10  106 M) for 15 min. Application of PACAP-38 (P) 2 
107 M as well as FSK (1  106 M) were not able to trigger Ca2
increase (representative of seven cells, five different cell cultures).
Scale: vertical, 20 nM; horizontal, 50 s. C, a first application of
PACAP-38 (P) 2  107 M elicited a Ca2 response. The second appli-
cation, after (Rp)-cAMPS (1  10
3 M) did not induce any response. In
all panels, thapsigargin (TG) is always able to elicit a large increase in
intracellular Ca2 (representative of four cells, four different cell cul-
tures). Scale: vertical, 100 nM; horizontal, 200 s.
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(Fig. 9B) similar to that obtained after depolarization using
KCl (30 mM) (Fig. 9C).
Because PACAP-38 increased [Ca2]i in human chromaffin
cells, the question arises as to whether these cells are capable
of catecholamine secretion. A carbon fiber (5 m) for ampero-
metric detection (41) was used to monitor catecholamine secre-
tion from cell clusters. Stimulation with PACAP-38 (5  107
M) in a 2 mM Ca2 medium, triggered the quantal release of
catecholamine by chromaffin cells as demonstrated by the oc-
currence of spikes under the carbon electrode (Fig. 10A, n  5).
If the cells are preincubated for 20 min with the PAC1-R an-
tagonist PACAP (6–38) (10 M), application of PACAP-38 (5 
107 M) failed to stimulate catecholamine release (Fig. 10B, n
4). Similar results were obtained if the cells are preincubated
with (Rp)-cAMPS (1 mM, 10 min) prior application of PACAP-38
(data not shown, n  2).
DISCUSSION
Our study demonstrates that the fetal human adrenal gland
expresses both type I and type II PACAP receptors. Activation
of chromaffin PACAP receptors with PACAP-38 induced a tran-
sient increase in [Ca2]i originating exclusively from intracel-
lular calcium pools and did not involve Ca2 influx from the
external medium. Moreover, the PACAP-sensitive Ca2 pool
was not mobilized by IP3 or TG. More importantly, PACAP-38
activated a ryanodine/caffeine-sensitive pool, which involved
cAMP and a phosphorylation step by PKA. In addition, we were
able to demonstrate that activation of the PAC1 receptor in-
duced secretion of catecholamine by the chromaffin cells.
The results presented herein indicate that, among the vari-
ous isoforms of the PACAP receptors, the short fragment and
one isoform A of an hip-hop insertion cassette of the PAC1
receptors are present in the human fetal adrenal gland at the
second trimester of gestation. By using PACAP (6–38), a PAC1
receptor-specific antagonist (32), we demonstrate that the Ca2
increase induced by PACAP-38 is mediated by the activation of
PAC1-R coupled to adenylyl cyclase (2).
One important finding of this study is the observation that
FIG. 8. PACAP-38 mobilizes Ca2 from a ryanodine/caffeine-
sensitive stores in the human fetal adrenal gland. A, addition of
caffeine (20 mM) triggered a Ca2 increase, revealing the presence of a
ryanodine/caffeine store. Emptying this store blunted the Ca2 re-
sponse to PACAP-38 (P) 1  109 M (representative of five cells, three
different cell cultures). Scale: vertical, 11 nM; horizontal, 100 s. B, cells
were treated for 10–15 min with Na3VO4 (100 M) and challenged
several times by PACAP-38 (P) 1  109 M. The amplitude of the Ca2
response decreased as a function of the number of trials (representative
of six cells from four different cell cultures). Scale: vertical, 10 nM;
horizontal, 50 s. C, plot of the amplitude of the Ca2 responses for
subsequent trials. 1, response in control conditions; 2, first response
after treatment with Na3VO4; 3, second response after Na3VO4; 4, third
response after Na3VO4; data are normalized to the amplitude of the first
response after Na3VO4 (bar number 2). Compilation of data from B. *,
significantly different at the p  0.05 level.
FIG. 9. Cholinergic agonists and KCl increase [Ca2]i in fetal
human chromaffin cells in the human fetal adrenal gland. A,
methacholine (10  106 M), a muscarinic agonist, induced a Ca2
increase when applied in the bath (representative of three cells, three
different cell cultures). Scale: vertical, 50 nM; horizontal, 200 s. B, Ca2
increase upon addition of nicotine (10 106 M) (representative of three
cells, three different cell cultures). Scale: vertical, 38 nM; horizontal,
200 s. C, depolarization by 30 mM KCl induced a Ca2 increase (repre-
sentative of three cells, three different cell cultures). Scale: vertical, 14
nM; horizontal, 50 s.
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the PACAP-induced Ca2 rise was not affected by the absence
of Ca2 in the external medium. This clearly indicated that
PACAP-38 does not trigger a Ca2 influx through channels or
exchangers, in agreement with data obtained in rat hippocam-
pal neurons (31). However, a number of reports indicate that
PACAP activates a Ca2 influx through various pathways,
including Ca2 channels (29, 42–44). In chromaffin cells from
adult human adrenal glands, voltage-dependent Ca2 channels
have been described (45), but no electrophysiological studies
have been performed in fetal cells. KCl depolarization, or ap-
plication of nicotine, were able to induce an increase in [Ca2]i
in human fetal chromaffin cells suggesting the presence of
functional voltage-dependent Ca2 channels. However, our re-
sults clearly show that these Ca2 channels were not involved
in PACAP-induced Ca2 increase.
The second most important feature of the present data was
that PACAP-responsive Ca2 pools were insensitive to TG. It
has been reported that TG triggers the release of Ca2 from
major nonmitochondrial Ca2 stores (46), including the IP3-
sensitive Ca2 pool (47). Our data conclusively demonstrate
that preincubation of the cells with TG or chronic application of
high concentrations of TG (8 M) have no effect on the Ca2
response triggered by PACAP-38. Previous experiments have
shown that, in human fetal chromaffin cells, PACAP-38 trig-
gered low production of IP3 (16). However, the present results,
using either the PLC inhibitor U73132 (35) or Xestospongin C,
a blocker of IP3 receptors (36), demonstrated that Ca
2 release
from IP3-sensitive Ca
2 stores did not contribute to the in-
crease in [Ca2]i triggered by PACAP-38.
Several lines of evidence pointed toward involvement of the
cAMP/PKA pathway in the [Ca2]i increase triggered by
PACAP-38 in human fetal chromaffin cells. FSK, which di-
rectly activates adenylyl cyclase to produce cAMP, triggered an
increase in Ca2 that was similar in amplitude and kinetics to
that induced by PACAP-38. Moreover, like PACAP-38, the re-
sponse triggered by FSK was independent of the presence of
Ca2 in the external medium. Additionally, blocking PKA us-
ing H-89 or (Rp)-cAMPS inhibited the effects of both PACAP-38
and FSK on [Ca2]i. Opposite results were found in hippocam-
pal neurons where PACAP-induced Ca2 response was not
triggered by FSK or (Bu)2cAMP and insensitive to H-89 (31).
Cyclic AMP-sensitive Ca2 stores have been described in nu-
merous cell types, but their relationship with the IP3- and the
ryanodine/caffeine Ca2 stores is still a matter of debate. In
several cell types, it has been shown that the ryanodine recep-
tor is subject to phosphorylation by several kinases, including
PKA (48, 49). Our results clearly indicated that PACAP- and
FSK-induced Ca2 increases were sensitive to PKA-dependent
phosphorylation. This, together with the effect of ryanodine/
caffeine, could indicate that PACAP-38 mobilizes Ca2 from
caffeine-sensitive stores in human fetal chromaffin cells.
Application of caffeine to human fetal chromaffin cells trig-
gered a moderate increase in [Ca2]i confirming the presence of
caffeine-sensitive Ca2 stores. In bovine adult chromaffin cells,
PACAP released Ca2 from a ryanodine/caffeine store (50),
which was independent of IP3, as observed for our cell model.
However, it was also reported that Ca2 rise was insensitive to
(Rp)-cAMPS contrary to human fetal chromaffin cells where
H-89, or (Rp)-cAMPS, completely inhibited both PACAP- and
FSK-inducedresponses.Theroleandweightinessof thecaffeine-
dependent Ca2 pools in chromaffin cells have been outlined by
several authors (51) who report that caffeine-dependent Ca2
pools release more Ca2 than IP3-dependent Ca
2 pools in
permeabilized chromaffin cells (52, 53). The signaling pathway
has not yet been fully characterized, although several possibil-
ities have been proposed (54). More recently, secretory vesicles
in neuroendocrine cells have been demonstrated to constitute a
dynamic Ca2 pool (38). Several features of the vesicle-Ca2
stores are similar to those defined by PACAP-dependent stores.
Indeed, these pools are insensitive to TG, are not mobilized by
IP3, and are sensitive to caffeine and ryanodine. As proposed by
Mitchell et al. (38), cytosolic Ca2 is pumped into the deep
vesicles by an ATP-dependent P-type Ca2 pump. Ca2 is re-
leased by primed vesicles located near the plasma membrane
when [Ca2]i concentrations increase due to Ca
2 channel
opening (55). Our data indicate that treatment of chromaffin
cells with Na3VO4 did not empty the PACAP-sensitive Ca
2
pools, as illustrated by identical levels of Ca2 increase ob-
tained before and after Na3VO4 application. However, the fact
that the amplitude of the subsequent responses to PACAP-38
decreased as a function of the number of PACAP-38 applica-
tions indicated that re-pumping of Ca2 may have been im-
paired by Na3VO4.
By using amperometry, we also demonstrated that human
fetal chromaffin cells release catecholamine in response to
PACAP-38. [Ca2]i increase is a requirement, as outlined by
the absence of secretion in cells treated with PACAP (6–38) or
(Rp)-cAMPS. Catecholamine secretion could be linked to the
paracrine control of secretion of dehydroepiandrosterone sul-
fate and cortisol by fetal steroidogenic cells. Indeed, in cell
cultures, PACAP-38 stimulates DHEA and cortisol secretion,
an effect abolished by preincubation with the -adrenoreceptor
antagonist, propranolol (15).
In summary, stimulation of chromaffin cells with PACAP-38
induced a cAMP-dependent increase in intracellular Ca2
whose properties and regulation exhibit particular features.
This model has thus enabled the identification of a novel path-
way in the regulation of cAMP-dependent Ca2 release, which
could be specific to fetal tissues. In addition to its role in
catecholamine secretion, PACAP-38 could act as a survival
factor for chromaffin cells, because, in contrast to fetal cells,
chromaffin cells do not undergo apoptosis, either in vivo or in
FIG. 10. Amperometric recordings of catecholamine secretion
by fetal human chromaffin cells. Current spikes were recorded by a
carbon electrode positioned near the cell. A, secretion induced by appli-
cation of PACAP-38 (P) 5  107 M. Scale: vertical, 0.8 pA; horizontal,
625 s. (representative of five cells, three different cells cultures). B, cells
were preincubated for 20 min in the presence of PACAP (6–38) 1 105
M and challenged with PACAP-38 (P) (5  107 M). Scale: vertical, 0.8
pA; horizontal, 800 s (representative of four cells, two different cells
cultures).
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vitro (56, 57). Recent studies conducted in knock-out mice for
PACAP, revealed that PACAP was not essential for normal
development of the adrenal gland, nor for basal catecholamine
secretion; however, its presence was essential for adaptive re-
sponses. Indeed, mice lacking PACAP were unable to survive in
response to a metabolic stress (58). Taken together, these re-
sults clearly indicate that PACAP is one of the important
factors necessary in maintaining adequate interaction between
catecholamine and steroid-producing cells, an interaction that
occurs during normal development.
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